Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer
William Greenhalf(University of Liverpool), Julia Mayerle(LMU Klinikum), David Goldstein(New South Wales Department of Health), Daniel H. Palmer(University of Liverpool), Andrew Scarfe(Cancer Institute (WIA)), John R. Mackey(University of Alberta), Markus W. Büchler(Heidelberg University), Nils Elander(University of Liverpool), Attila Oláh(Semmelweis University), John P. Neoptolemos(University of Liverpool), Bengt Glimelius(Uppsala University), Richard Charnley(Newcastle upon Tyne Hospitals NHS Foundation Trust), Karen Aughton(University of Liverpool), Juan W. Valle(Cancer Research UK Manchester Institute), Niall C. Tebbutt(Austin Health), Alan Anthoney(St James's University Hospital), Christopher Halloran(University of Liverpool), Trevor F. Cox(University of Liverpool), Markus M. Lerch(Ludwig-Maximilians-Universität München), Fiona Campbell(University of Birmingham), Christos Dervenis(Agia Olga Hospital), P. Ghaneh, J. Shannon(The University of Sydney), A. McDonald(Cancer Research UK), R. Carter(Cancer Research UK), Eithne Costello(University of Liverpool), Mark Deakin(John Radcliffe Hospital)
Cited by 34
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k